KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accounts Payables: 2011-2025

Historic Accounts Payables for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $108.6 million.

  • Supernus Pharmaceuticals' Accounts Payables rose 43.28% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.6 million, marking a year-over-year increase of 43.28%. This contributed to the annual value of $76.4 million for FY2024, which is 4.04% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Accounts Payables of $108.6 million as of Q3 2025, which was up 39.71% from $77.7 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Accounts Payables ranged from a high of $133.0 million in Q2 2022 and a low of $70.1 million during Q1 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Accounts Payables value was $79.6 million (recorded in 2023), while the average stood at $83.7 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Accounts Payables soared by 112.40% in 2021 and then crashed by 37.56% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Accounts Payables (Quarterly) stood at $117.7 million in 2021, then fell by 18.13% to $96.3 million in 2022, then declined by 17.41% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024, then skyrocketed by 43.28% to $108.6 million in 2025.
  • Its Accounts Payables was $108.6 million in Q3 2025, compared to $77.7 million in Q2 2025 and $76.9 million in Q1 2025.